The C4A and C4B isotypic forms of human complement fragment C4b have the same intrinsic affinity for complement receptor 1 (CR1/CD35)

被引:11
作者
Clemenza, L
Isenman, DE
机构
[1] Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada
[2] Univ Palermo, Dept Biopathol & Biomed Methodol, Palermo, Italy
关键词
D O I
10.4049/jimmunol.172.3.1670
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Several previous reports concluded that the C4b fragment of human C4A (C4Ab) binds with higher affinity to CR1 than does C4Bb. Because the isotypic residues, (PCPVLD)-P-1101 and (LSPVIH)-L-1101 in C4A and C4B, respectively, are located within the C4d region, one may have expected a direct binding contribution of C4d to the interaction with CR1. However, using surface plasmon resonance as our analytical tool, with soluble rCR1 immobilized on the biosensor chip, we failed to detect significant binding of C4d of either isotype. By contrast, binding of C4c was readily detectable. C4A and C4B, purified from plasma lacking one of the isotypes, were C(1) over bar s converted to C4Ab and C4Bb. Spontaneously formed disulfide-linked dimers were separated from monomers and higher oligomers by sequential chromatographic steps. The binding sensorgrams of C4Ab and C4Bb monomers as analytes reached steady state plateaus, and these equilibrium data yielded essentially superimposable saturation curves that were well fit by a one-site binding model. Although a two-site model was required to fit the equilibrium-binding data for the dimeric forms of C4b, once again there was little difference in the K, values obtained for each isotype. Independent verification of our surface plasmon resonance studies came from ELISA-based inhibition experiments in which monomers of C4Ab and C4Bb were equipotent in inhibiting the binding of soluble CRI to plate-bound C4b. Although divergent from previous reports, our results are consistent with recent C4Ad structural data that raised serious doubts about there being a conformational basis for the previously reported isotypic differences in the C4b-CR1 interaction.
引用
收藏
页码:1670 / 1680
页数:11
相关论文
共 53 条
[1]  
ATKINSON JP, 1989, CLIN EXP RHEUMATO S3, V7, P95
[2]  
BECHERER JD, 1988, J BIOL CHEM, V263, P14586
[3]   Genetic, structural and functional diversities of human complement components C4A and C4B and their mouse homologues, Slp and C4 [J].
Blanchong, CA ;
Chung, EK ;
Rupert, KL ;
Yang, Y ;
Yang, ZY ;
Zhou, B ;
Moulds, JM ;
Yu, CY .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2001, 1 (03) :365-392
[4]   Deficiencies of human complement component C4A and C4B and heterozygosity in length variants of RP-C4-CYP21-TNX (RCCX) modules in Caucasians:: The load of RCCX genetic diversity on major histocompatibility complex-associated disease [J].
Blanchong, CA ;
Zhou, B ;
Rupert, KL ;
Chung, EK ;
Jones, KN ;
Sotos, JF ;
Zipf, WB ;
Rennebohm, RM ;
Yu, CY .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (12) :2183-2196
[5]   SUBSTITUTION OF A SINGLE AMINO-ACID (ASPARTIC-ACID FOR HISTIDINE) CONVERTS THE FUNCTIONAL-ACTIVITY OF HUMAN-COMPLEMENT C4B TO C4A [J].
CARROLL, MC ;
FATHALLAH, DM ;
BERGAMASCHINI, L ;
ALICOT, EM ;
ISENMAN, DE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (17) :6868-6872
[6]   Complement C4 inhibits systemic autoimmunity through a mechanism independent of complement receptors CR1 and CR2 [J].
Chen, ZB ;
Koralov, SB ;
Kelsoe, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (09) :1339-1351
[7]   IMMUNE ADHERENCE BY FOURTH COMPONENT OF COMPLEMENT [J].
COOPER, NR .
SCIENCE, 1969, 165 (3891) :396-&
[8]   The reaction mechanism of the internal thioester in the human complement component C4 [J].
Dodds, AW ;
Ren, XD ;
Willis, AC ;
Law, SKA .
NATURE, 1996, 379 (6561) :177-179
[9]   Lack of evidence of a specific role for C4A gene deficiency in determining disease susceptibility among C4-deficient patients with systemic lupus erythematosus (SLE) [J].
Dragon-Durey, MA ;
Rougier, N ;
Clauvel, JP ;
Caillat-Zucman, S ;
Remy, P ;
Guillevin, L ;
Liote, F ;
Blouin, J ;
Ariey, F ;
Lambert, BU ;
Kazatchkine, MD ;
Weiss, L .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2001, 123 (01) :133-139
[10]  
DUNCKLEY H, 1987, J IMMUNOGENET, V14, P209